Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.
Celgene has worldwide development and commercialization rights.
Agios has U.S. co –promotion and royalty rights.
Joint worldwide collaboration with Celgene.
The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.